Business Overview: MariMed Inc. (OTCQX: MRMD)

---

Executive Summary

MariMed Inc. is a multi-state cannabis operator (MSO) headquartered in Norwood, Massachusetts, that develops, owns, and manages licensed, seed-to-sale cannabis facilities — cultivation, manufacturing, and retail dispensing — for medical and adult-use cannabis. The company holds 33 cannabis licenses across six states and is fully vertically integrated (growing, processing, and retailing under one roof) in Illinois, Maryland, Massachusetts, and Delaware.

MariMed generated $159.8 million in revenue in fiscal 2025, modestly up from $157.7 million in 2024, through a network of 13 operating dispensaries and wholesale distribution of its own branded products into hundreds of third-party dispensaries. Because cannabis remains illegal under federal law, MariMed operates entirely within individual state regulatory frameworks, a defining feature of its business and risk profile.

---

1. Core Business Model & How They Work

MariMed runs a dual-channel cannabis business: it wholesales its own branded flower, concentrates, and edibles to hundreds of dispensaries operated by other license holders, and it retails directly to consumers through its own branded Thrive dispensaries.

[ Licensed Cultivation (MA, DE, IL, MD, OH) ] ➡️ [ Processing & Branded Product Manufacturing ] ➡️ [ Wholesale to 3rd-Party Dispensaries ] + [ Retail via Company-Owned "Thrive" Dispensaries ] ➡️ [ Consumer / Patient ]

Because cannabis cannot cross state lines, MariMed must build or license a full cultivation-to-retail supply chain separately in every state it operates in — a structural feature of the U.S. cannabis industry that favors companies like MariMed with established, multi-state licenses and operating infrastructure over new entrants who must build from scratch in each jurisdiction.

---

2. Business Segments

MariMed does not break out formal reporting segments beyond revenue channel; its two core channels in FY2025 were:

                      ┌─────────────────────────┐
                      │       MariMed Inc.         │
                      └─────────────┬─────────────┘
                                    │
                 ┌──────────────────┴──────────────────┐
                 │                                       │
     ┌───────────▼────────────┐           ┌─────────────▼─────────────┐
     │   Retail Product Revenue │           │  Wholesale Product Revenue │
     │        $89.0M (56%)      │           │        $69.6M (44%)        │
     │   (13 company dispens.)  │           │  (branded products sold    │
     │                           │           │   into 3rd-party dispens.) │
     └───────────────────────────┘           └─────────────────────────────┘

Retail sales come from MariMed's 13 company-operated Thrive-branded dispensaries across Massachusetts (3), Illinois (5), Delaware (2), Maryland (2), and Ohio (1), plus home delivery in Massachusetts and Delaware.

Wholesale sales — the faster-growing channel, up ~11% in 2025 — come from MariMed's cultivation and processing facilities (New Bedford and Quincy, MA; Milford, DE; Mt. Vernon, IL; Hagerstown, MD) supplying its branded products to hundreds of dispensaries run by other operators, supported by dedicated sales teams.

---

3. Product Portfolio

---

4. Competitive Landscape

MariMed competes against other multi-state operators (MSOs) and single-state licensees, with competitive intensity varying by state:

• National MSO peers: Curaleaf, Trulieve, Green Thumb Industries, Verano Holdings, and Cresco Labs — all larger-scale multi-state operators competing for cultivation licenses, dispensary real estate, and wholesale shelf space.
• State-specific competition: In each of MariMed's core states (Massachusetts, Illinois, Maryland, Delaware, Ohio), a mix of other vertically-integrated MSOs and local single-state operators compete directly for retail and wholesale market share.
• Competitive factors: MariMed describes itself as operating "one of the lowest cost structures in the industry," positioning on cost efficiency and brand breadth (six distinct brands spanning flower, edibles, and beverages) rather than being a single-product player.

Regulatory licensing, capital requirements, and compliance complexity are themselves meaningful barriers to entry that favor established operators like MariMed over new entrants.

---

5. Strategic Strengths & Risks

Strengths (the moat): MariMed's core advantage is its established, vertically-integrated license portfolio — 33 licenses across six states, with full seed-to-sale control in four of them — which is extremely difficult and slow for a new entrant to replicate given state-by-state licensing caps and application processes. Its brand diversification (Nature's Heritage, Betty's Eddies, Bubby's Baked, Vibations, InHouse) spreads revenue across flower, edibles, and beverages rather than depending on a single product category, and the growing wholesale channel (+11% in 2025) extends its reach beyond its own retail footprint.

Risks: Cannabis remains illegal under U.S. federal law, meaning MariMed operates under constant legal, banking, and tax (IRC Section 280E) friction that ordinary companies don't face, and any adverse federal or state regulatory shift could be existential. FY2025 profitability deteriorated — GAAP gross margin fell to 36.2% from 39.7%, Adjusted EBITDA declined to $16.9 million from $19.3 million, and the company posted a GAAP net loss of $14.5 million — reflecting pricing pressure typical of maturing, increasingly commoditized state cannabis markets. The company also carries $24.0 million in goodwill and $17.2 million in intangible assets, exposing it to potential future impairment risk if any state market underperforms.

---

6. Financial Overview

---

7. Summary Conclusion

MariMed has built a genuinely diversified, vertically-integrated cannabis platform across six states, with brand breadth spanning flower, edibles, and beverages and a wholesale business that is now growing faster than its retail footprint. The company's core moat — hard-won, state-specific cultivation and dispensary licenses — remains intact and difficult to replicate, but FY2025 results show the broader cannabis industry's maturing-market dynamics catching up with MariMed: shrinking margins, a widening GAAP net loss, and retail revenue that actually declined. With expansion underway into Pennsylvania (2027) and New York (2027), the key forward question is whether MariMed's wholesale and brand-licensing growth can outpace continued price erosion in its legacy retail markets.